Supernus Pharmaceuticals (SUPN) Tops Q2 EPS by 1c, Updates Guidance

Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q2 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $35.1 million versus the consensus estimate of $34.27 million.

Financial Guidance

The Company is updating its full year 2015 financial guidance for both expected net product sales and operating income. The Company expects that net product sales will range from $135 million to $140 million, with operating income ranging from $8 million to $10 million. This compares to prior guidance of net product sales of $130 million to $140 million and operating income of $6 million to $10 million.

For earnings history and earnings-related data on Supernus Pharmaceuticals (SUPN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight